Kairos Pharma Marks Successful IPO
Kairos Pharma, Ltd. (NYSE American: KAPA), a biopharmaceutical company in the clinical stage that focuses on developing cancer therapies, has successfully closed its initial public offering (IPO). Through the sale of 1,550,000 shares of common stock priced at $4.00 each, the company raised an impressive $6.2 million.
How the Funds Will Be Used
The money from this IPO will be crucial in helping Kairos Pharma fulfill its mission of creating innovative treatments to tackle issues like cancer drug resistance and immune system suppression. The company plans to use the net proceeds to fund its Phase 1 clinical trial for ENV 105 in lung cancer and a Phase 2 trial for prostate cancer. This lead product candidate aims to address the challenges posed by resistance to current cancer therapies.
Advancement of Preclinical Candidates
Beyond the clinical trials, the funds will also support the development of preclinical candidates such as KROS 101. This small molecule agonist is designed to target the GITR ligand, boosting T cell growth and enhancing their ability to attack cancer cells. This effort reflects Kairos Pharma's dedication to building a strong pipeline of cancer therapies.
Underwriters and Legal Representation
Boustead Securities, LLC led the IPO as the managing underwriter, while EF Hutton LLC and Sutter Securities, Inc. served as co-managing underwriters. Legal support for the company was provided by Dorsey & Whitney LLP, and Olshan Frome Wolosky LLP represented the underwriters.
About the Company
Established in Los Angeles, California, Kairos Pharma is committed to using structural biology to develop drugs that not only fight cancer but also help to reverse its impact on the immune system. The company has established a unique position in the oncology field with its diverse range of therapeutics.
Regulatory Approvals and Registration
The Securities and Exchange Commission (SEC) declared the registration statement for this offering effective before trading commenced. Following best practices, the offering was conducted strictly via a prospectus. Electronic copies of the final prospectus will be available on the SEC’s official website for interested parties.
Contact Information
For more information, individuals and companies can contact Louie Toma at CORE IR via email at investors@kairospharma.com. This provides a direct line of communication for potential investors seeking further details.
Frequently Asked Questions
What is the purpose of the funds raised from the IPO?
The funds raised will support clinical trials for ENV 105 and advance preclinical candidates such as KROS 101.
Who managed Kairos Pharma's IPO?
Boustead Securities, LLC acted as the lead managing underwriter for the IPO, assisted by EF Hutton LLC and Sutter Securities, Inc.
What is ENV 105?
ENV 105 is Kairos Pharma's lead product candidate aimed at reversing resistance to cancer drugs, currently being tested in clinical trials.
Where is Kairos Pharma located?
Kairos Pharma is based in Los Angeles, California, focusing on innovative cancer therapeutics.
How can one access the final prospectus?
The final prospectus will be available on the SEC's website once it is published, providing detailed information about the IPO.
